Infectious Disease Molecular Diagnostics Market: Trends, Size, Share, and Forecast (2025-2034)

Overview of the Infectious Disease Molecular Diagnostics Market

The infectious disease molecular diagnostics market has become a cornerstone of modern healthcare, enabling early, accurate, and rapid detection of infectious pathogens. By leveraging advanced molecular technologies such as PCR (polymerase chain reaction), NGS (next-generation sequencing), and isothermal nucleic acid amplification, these diagnostics allow clinicians to identify diseases ranging from influenza and HIV to COVID-19 and emerging viral threats.

Get a free sample report: https://bit.ly/41sb9z1

In 2024, the global infectious disease molecular diagnostics market was valued at USD 35.87 billion. The growth trajectory is influenced by an increasing geriatric population, rising global incidence of infectious diseases, and continuous technological advancements in diagnostic devices. With a projected CAGR of 3.20% from 2025 to 2034, the market is set to reach USD 49.15 billion by 2034.

The expansion of point-of-care testing, integration of AI-driven analysis tools, and growing adoption in low- and middle-income countries are reshaping the industry landscape.

Infectious Disease Molecular Diagnostics Market Size & Share

The market's growth is underpinned by both epidemic-driven demand surges and the ongoing burden of chronic infectious diseases.

Regional Market Share (2024):

North America: ~38% - Leading due to strong healthcare infrastructure, advanced lab capabilities, and high testing volumes.

Europe: ~30% - Benefiting from government-led disease surveillance programs and adoption of molecular testing in public healthcare.

Asia-Pacific: ~24% - Experiencing rapid growth due to urbanization, population density, and rising investments in healthcare.

Rest of the World: ~8% - Driven by international funding for infectious disease control.

The dominance of PCR-based tests remains strong, but NGS is rapidly gaining adoption in research and clinical settings, particularly for pathogen discovery and antimicrobial resistance profiling.

Market Dynamics & Trends

Key Growth Drivers

Rising Infectious Disease Burden: Outbreaks of respiratory infections, sexually transmitted diseases, and vector-borne diseases are increasing global testing needs.

Technological Innovation: Portable molecular diagnostic devices and multiplex panels are revolutionizing pathogen detection.

Aging Population: Older adults are more susceptible to severe infections, increasing testing demand.

Global Health Initiatives: WHO and CDC-led programs supporting large-scale screening campaigns.

Emerging Trends

Point-of-Care Molecular Testing: Delivering results in under an hour for use in clinics, emergency rooms, and remote areas.

AI-Enhanced Diagnostics: Automated interpretation of genetic sequences for faster pathogen identification.

Multiplex Assays: Single tests capable of detecting multiple pathogens simultaneously.

Decentralized Testing Models: Expansion into non-traditional healthcare settings such as pharmacies.

Restraining Factors

High Costs of Advanced Platforms: Limiting adoption in low-resource settings.

Regulatory Delays: Stringent approval processes slow market entry for innovative technologies.

Skilled Workforce Requirements: Need for trained personnel to operate and interpret complex tests.

Read full report with table of content: https://bit.ly/456mzuK

Growth Outlook of the Infectious Disease Molecular Diagnostics Market

From 2025 to 2034, the market is expected to maintain steady growth, expanding from USD 35.87 billion to USD 49.15 billion. Demand will be fueled by:

Increasing prevalence of drug-resistant pathogens.

Greater investment in pandemic preparedness infrastructure.

Wider use of molecular testing in veterinary and environmental monitoring.

The shift from centralized laboratories toward decentralized, rapid testing solutions will be a defining factor in future market expansion.

Market Opportunities and Challenges

Opportunities

Expansion in Emerging Markets: Rising healthcare spending in Asia-Pacific, Africa, and Latin America.

Portable Diagnostic Platforms: Enabling rapid testing during outbreaks in rural and disaster-hit areas.

Integration with Digital Health Platforms: Real-time disease tracking and data sharing for public health management.

Genomic Surveillance: Leveraging molecular diagnostics for epidemiological mapping.

Challenges

Cost Constraints: Advanced molecular platforms remain expensive to procure and operate.

Infrastructure Gaps: Limited laboratory capacity in developing regions.

Data Privacy Concerns: Especially for genetic and pathogen data storage.

Recent Developments in the Market

Roche expanded its cobas® platform offerings with new multiplex respiratory panels.

Abbott launched portable molecular COVID-19 and flu testing kits with rapid turnaround.

bioMérieux introduced advanced syndromic panels for sepsis and meningitis diagnostics.

Hologic enhanced its Panther Fusion® system with high-throughput viral load testing.

QIAGEN partnered with public health agencies for large-scale TB testing in high-burden countries.

Competitor Analysis

The infectious disease molecular diagnostics market is competitive, with established multinational corporations leading innovation, while regional players target affordability and accessibility.

Key Players

Becton, Dickinson and Company

A global leader in diagnostic systems, BD offers molecular platforms such as the BD MAXTM System for rapid pathogen detection.

bioMérieux SA

Specializes in infectious disease diagnostics with strengths in syndromic testing and antimicrobial resistance detection.

QIAGEN

Renowned for sample preparation and molecular assay solutions, supporting both research and clinical diagnostics.

F. Hoffmann-La Roche Ltd

Offers the cobas® series of automated molecular platforms, widely used in hospitals and labs worldwide.

Abbott

Provides point-of-care and laboratory-based molecular diagnostic tests, including ID NOWTM and m2000 systems.

Danaher Corporation

Through subsidiaries like Cepheid, offers rapid, cartridge-based PCR solutions for multiple infectious diseases.

Agilent Technologies, Inc.

Develops molecular detection systems with a strong focus on research applications and translational diagnostics.

Hologic, Inc.

Known for its Panther® systems, providing high-throughput molecular testing solutions for STIs and respiratory infections.

Sysmex Corporation

Offers molecular and hematology diagnostics with expanding applications in infectious disease testing.

Illumina, Inc.

Leads in next-generation sequencing, playing a pivotal role in genomic surveillance of pathogens.

FAQs about the Infectious Disease Molecular Diagnostics Market

Q. What is the primary purpose of molecular diagnostics in infectious diseases?
They detect specific genetic material from pathogens, enabling early and accurate diagnosis.

Q. Which technology dominates the market?
PCR remains the most widely used, though NGS adoption is growing for complex pathogen identification.

Q. What factors are driving market growth?
Increasing disease prevalence, technological innovations, and global health preparedness initiatives.

Q. Which regions are leading the market?
North America and Europe dominate, but Asia-Pacific is the fastest-growing region.

Q. What is the market forecast for 2034?
The market is expected to reach USD 49.15 billion, growing at a CAGR of 3.20%.

Find More Blog:

Peptide Therapeutics Market: https://bit.ly/4o0mekJ

Bone Cement Market: https://bit.ly/4o0R7W0

Clinical Microbiology Market: https://bit.ly/4eX362M

Active Pharmaceutical Ingredients (API) Market: https://bit.ly/4mabmPB

Self-Testing Market: https://bit.ly/3GVd8Fb

Media Contact:

Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Digital Marketing
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

This release was published on openPR.